Imaginepharma

Imagine Pharma, a Pittsburgh-based biotechnology firm founded in 2016, is focused on developing treatments for diseases with limited medical options. The company was established by Dr. Ngoc L. Thai, an internationally recognized transplant surgeon, who also serves as co-CEO and Chief Medical Officer. Dr. Thai's journey began after discovering the IMG-1 polypeptide in a tea plant from his native Vietnam. This discovery is now the cornerstone of the company's research and development. He is joined by co-CEO Santiago Pujadas, who brings extensive management experience to the team.

Imagine Pharma's business revolves around its core discovery, the IMG-1 polypeptide, which has led to the creation of three distinct development platforms: Oral Delivery, Therapeutics, and Regenerative Medicine. These platforms are aimed at creating first-in-class programs to address various disease states in large, underserved markets. The company's business model encompasses multiple revenue paths, including the commercialization of a nutritional supplement, strategic partnerships, licensing agreements, and providing islet isolation services. In a significant milestone, the company was selected by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as an approved Islet Isolation Center, supplying research-grade human islets to major academic diabetes centers.

The company's product pipeline is diverse. The Oral Delivery platform is working on making injections a thing of the past by developing oral versions of biologics like erythropoietin and GLP-1 receptor agonists. The Therapeutics platform is developing treatments to accelerate healing for skin donor sites and diabetic wounds. Most notably, the Regenerative Medicine platform is pioneering a potential cure for Type 1 diabetes by using IMG-1 to regenerate and propagate insulin-producing islet cells from a patient's own pancreas for autologous transplantation. In October 2023, Imagine Pharma secured $32.5 million in a Series A funding round led by IP Investors LLC, bringing its total funding to $40 million to advance these programs.

Keywords: polypeptide therapeutics, regenerative medicine, oral biologics delivery, diabetes treatment, IMG-1 polypeptide, cell therapy, islet isolation, Ngoc Thai, transplant surgery, metabolic disease research, cardiovascular disease drugs, wound healing, autologous cell therapy, GLP-1 agonists, erythropoietin, drug discovery, preclinical studies, biotechnology, Series A funding, Pittsburgh biotech